Immunome, Inc. to Post Q1 2025 Earnings of ($0.78) Per Share, Wedbush Forecasts (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for Immunome in a research report issued on Monday, April 1st. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.78) for the quarter. Wedbush has a "Outperform" rating and a $33.00 price target on the stock. The consensus estimate for Immunome's current full-year earnings is ($1.46) per share. Wedbush also issued estimates for Immunome's Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.78) EPS and Q4 2025 earnings at ($0.80) EPS.

IMNM has been the subject of several other research reports. SVB Leerink assumed coverage on shares of Immunome in a research note on Monday, January 29th. They set an "outperform" rating and a $30.00 price target for the company. Leerink Partnrs reaffirmed an "outperform" rating on shares of Immunome in a research note on Monday, January 29th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $31.50.

Immunome Trading Up 1.0 %

Shares of Immunome stock traded up $0.21 on Wednesday, hitting $21.60. 677,948 shares of the company traded hands, compared to its average volume of 710,965. The stock's 50 day moving average price is $22.80 and its 200-day moving average price is $13.88. Immunome has a 52 week low of $4.44 and a 52 week high of $30.96. The company has a market cap of $1.29 billion, a PE ratio of -3.97 and a beta of 1.66.

Institutional Investors Weigh In On Immunome

A number of large investors have recently made changes to their positions in IMNM. Natixis purchased a new stake in shares of Immunome during the fourth quarter valued at $25,000. Dorsey Wright & Associates acquired a new position in Immunome during the third quarter valued at $26,000. UBS Group AG lifted its position in Immunome by 1,049.9% during the third quarter. UBS Group AG now owns 15,271 shares of the company's stock valued at $68,000 after purchasing an additional 13,943 shares during the period. Renaissance Technologies LLC lifted its position in Immunome by 53.6% during the second quarter. Renaissance Technologies LLC now owns 21,500 shares of the company's stock valued at $69,000 after purchasing an additional 7,500 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Immunome during the first quarter valued at $77,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.